Amgen’s Neulasta Ad Indirectly Targeting Biosimilars Draws US FDA Rebuke

 
• By Brenda Sandburg
  
FDA objects to Amgen's Neulasta promotion • Source: illustration/FDA

More from Marketing & Advertising

More from Compliance